BioMarin Pharmaceutical Inc. (BMRN) Earnings Call Transcripts
BioMarin Pharmaceutical Inc.'s Latest Earnings Call - Q1 FY2026
BioMarin Pharmaceutical Inc. reported its Q1 2026 earnings with total revenues of $766 million, driven by strong demand for enzyme therapies and VOXZOGO, despite some order timing dynamics. The recent acquisition of Amicus Therapeutics is expected to accelerate revenue growth to 20% for FY2026, with updated guidance reflecting a range of $3.825 billion to $3.925 billion. Non-GAAP EPS for the quarter was $0.76, impacted by increased operating expenses and a $31 million charge related to NAGLAZYME manufacturing. Full-year EPS guidance was updated to $4.85 to $5.05, incorporating the Amicus acquisition, which is expected to be accretive by 2027.
Reported metrics
| Metric | Value |
|---|---|
| Total Revenue | $766 million (inline) |
| Non-GAAP EPS | $0.76 (miss) |
| Enzyme Therapies Revenue | 6% YoY growth (beat) |
| VOXZOGO Revenue Guidance | $975 million to $1.025 billion (inline) |
| Full Year Revenue Guidance | $3.825 billion to $3.925 billion (positive) |
| Non-GAAP EPS Guidance | $4.85 to $5.05 (inline) |
Guidance from management
BioMarin raised its full-year 2026 revenue guidance to $3.825 billion to $3.925 billion, reflecting 20% growth at the midpoint. The enzyme therapies revenue guidance was increased to $2.725 billion to $2.775 billion, with the acquisition of Amicus expected to be slightly dilutive in 2026 but accretive by 2027.
What management said
And Jason, if I could just add one other factor from the medical affairs standpoint. -- we're obviously actively working in the community even prior to seeing our data to really try to accelerate the number of patients that are diagnosed with this condition. There's probably 3 prongs to that. Of course, getting patients to be able to be referred sooner, to be evaluated, of course, more testing as well as we're doing ...
To throw out a few components, if I could, quickly. On the success we've had already, when looking at the diagnosis program that we're running to date and these kind of nonpromotional prelaunch activities, we're already seeing a 90% increase in the number of hypochondroplasia patients that we've identified as well as a 70% reduction in the age. So those are precisely the types of numbers that we're driving for and w...
What analysts pressed on
Analysts questioned the potential impact of competitor entries on VOXZOGO and the integration strategy for Amicus. Concerns were raised about the timing of revenue recognition and the potential for manufacturing workarounds in the ITC case against Ascendis.
Main topics on the call
- Amicus Acquisition — BioMarin completed the acquisition of Amicus, adding Galafold and Pombiliti and Opfolda to its portfolio. This is expected to drive a 20% revenue growth in 2026. Management stated, 'The acquisition accelerates our antici...
- VOXZOGO Performance — VOXZOGO saw strong patient demand with new patient starts increasing, particularly in the under age 2 cohort. Management noted, 'In Q1, over half of new patient starts were from children under age 2.'
- PALYNZIQ Expansion — PALYNZIQ's label expansion to adolescents is expected to drive growth, with management observing 'encouraging early momentum' in the under 18 population.
- R&D Pipeline — BioMarin is progressing with pivotal data readouts for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency expected in Q2 2026. Management expressed confidence in the 'strong proof of concept and durability' fo...
Read the full BioMarin Pharmaceutical Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 118 calls on record spanning January 9, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 118 BioMarin Pharmaceutical Inc. earnings call transcripts on record, spanning January 9, 2020 to August 6, 2026. Based on this history, BioMarin Pharmaceutical Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BMRN
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 118
- First call
- January 9, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly